| Literature DB >> 24498015 |
Azucena Mora1, Ghizlane Dahbi1, Cecilia López1, Rosalía Mamani1, Juan Marzoa1, Sara Dion2, Bertrand Picard3, Miguel Blanco1, María Pilar Alonso4, Erick Denamur2, Jorge Blanco1.
Abstract
Escherichia coli sequence type (ST)131 is an emerging disseminated public health threat implicated in multidrug-resistant extraintestinal infections worldwide. Although the majority of ST131 isolates belong to O25b:H4 serotype, new variants with different serotypes, STs using the discriminative multilocus sequence typing scheme of Pasteur Institute, and virulence-gene profiles (virotypes) have been reported with unknown implications on the pattern of spread, persistence and virulence. The aim of the present study was to compare virulence in a mouse subcutaneous sepsis model of representative ST131 clinical isolates belonging to 2 serotypes (O25b:H4, O16:H5) and nine virotypes and subtypes (A, B, C, D1, D2, D3, D4, D5 and E). Fourteen out of the 23 ST131 isolates tested (61%) killed 90 to 100% of mice challenged, and 18 of 23 (78%) at least 50%. Interestingly, different virulence patterns in association with virotypes were observed, from highly rapid lethality (death in less than 24 h) to low final lethality (death at 7 days) but with presence of an acute inflammation. This is the first study to assess virulence of ST131 isolates belonging to serotype O16:H5, which exhibited virotype C. In spite of their low virulence-gene score, O16:H5 isolates did not show significant differences in final lethality compared with highly virulent O25b:H4 isolates of virotypes A, B and C, but killed mice less rapidly. Significant differences were found, however, between virotypes A, B, C (final lethality ≥80% of mice challenged) and virotypes D, E. Particularly unexpected was the low lethality of the newly assigned virotype E taking into account that it exhibited high virulence-gene score, and the same clonotype H30 as highly virulent O25b:H4 isolates of virotypes A, B and C. In vivo virulence diversity reported in this study would reflect the genetic variability within ST131 clonal group evidenced by molecular typing.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24498015 PMCID: PMC3907423 DOI: 10.1371/journal.pone.0087025
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of the 23 ST131 extraintestinal E. coli clinical isolates studied.
| Isolate code | Year | Province (Spain) | Clinic origin | Serotype | Phylogroup | STAtchman | Virotype | BLEEtype | Antibioticresistances | Reference |
| FV 9873 | 2007 | Lugo | UTI | O25b:H4 | B2 | 131 | A | CTX-M-15 | NAL CIP SXT TOB |
|
| FV 7563 | 2006 | Lugo | UTI | O25b:H4 | B2 | 131 | A | CTX-M-15 | NAL CIP SXT TOB |
|
| 35 BA | 2008 | Barcelona | UTI | O25b:H4 | B2 | 131 | B | CTX-M-15 | NAL CIP SXT GEN TOB |
|
| 25.27 | 2006 | Madrid | Pneumonia (sputum) | O25b:H4 | B2 | 131 | B | CTX-M-15 | NAL CIP SXT GEN TOB |
|
| 20.22 | 2006 | A Coruña | UTI | O25b:H4 | B2 | 131 | C | CTX-M-14, CTX-M-15 | NAL CIP SXT GEN TOB AMC FOF |
|
| 45.09 | 2006 | Valencia | UTI | O25b:H4 | B2 | 131 | C | CTX-M-15 | NAL CIP SXT GEN TOB AMC |
|
| 28.65 | 2006 | Madrid | UTI | O25b:H4 | B2 | 131 | D | CTX-M-14 | NAL CIP SXT TOB |
|
| H1447 | 2004 | Lugo | Bacteremia | O25b:H4 | B2 | 131 | D | NAL SXT |
| |
| FV 11171 | 2008 | Lugo | Bacteremia | O25b:H4 | B2 | 131 | D | CTX-M-9 | SXT GEN TOB AMC |
|
| H2525 | 2008 | Lugo | Bacteremia | O25b:H4 | B2 | 131 | D |
| ||
| H1659 | 2005 | Lugo | Bacteremia | O25b:H4 | B2 | 131 | D |
| ||
| H2341 | 2008 | Lugo | Bacteremia | O25b:H4 | B2 | 131 | D | SXT |
| |
| FV 14025 | 2009 | Lugo | UTI | O25b:H4 | B2 | 131 | D | CTX-M-9 | NAL SXT |
|
| 83 BA | 2008 | Barcelona | UTI | O25b:H4 | B2 | 131 | D | SHV-12 | NAL |
|
| FV 17616 | 2012 | Lugo | UTI | O25b:H4 | B2 | 131 | D | CTX-M-1 | NAL CIP SXT AMC |
|
| 61 BA | 2008 | Barcelona | Abscess (pus) | O25b:H4 | B2 | 131 | D | SHV-12 | NAL CIP SXT |
|
| 50 BA | 2008 | Barcelona | UTI | O25b:H4 | B2 | 131 | D | CTX-M-14 | NAL SXT |
|
| FV17578 | 2012 | Lugo | UTI | O25b:H4 | B2 | 131 | New | CTX-M-15 | NAL CIP TOB |
|
| FV 17543 | 2012 | Lugo | UTI | O25b:H4 | B2 | 131 | New | CTX-M-15 | NAL CIP SXT |
|
| FV 17539 | 2012 | Lugo | UTI | O16:H5 | B2 | 131 | C | CTX-M-14 | NAL CIP SXT GEN TOB |
|
| FV 17598 | 2012 | Lugo | UTI | O16:H5 | B2 | 131 | C | CTX-M-14 | NAL CIP SXT GEN TOB |
|
| H2623 | 2009 | Lugo | Bacteremia | O16:H5 | B2 | 131 | C | NAL CIP | This study | |
| FV 13998 | 2009 | Lugo | UTI | O16:H5 | B2 | 131 | C | CTX-M-14 | NAL FOF | This study |
Resistances against betalactam antibiotics are not included here. NAL = nalidixic acid, CIP = ciprofloxacin, SXT = trimethoprim-sulfamethoxazole, TOB = tobramycin, GEN = gentamicin, AMC = amoxicillin/clavulanic acid, FOF = fosfomycin.
Virulence-gene scheme for defining ST131 E. coli virotypes.
| Virotype | Virulence genes | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |
| A | − | − | +/− | + | + | − | − | − | − | − | − |
| B | − | + | +/− | − | − | − | − | − | − | − | − |
| C | − | − | + | − | − | − | − | − | − | − | − |
| D1 | + | +/− | − | − | − | − | − | − | − | + | − |
| D2 | + | +/− | − | − | − | − | + | − | − | + | − |
| D3 | + | +/− | +/− | +/− | +/− | − | − | − | − | − | − |
| D4 | + | +/− | − | − | − | − | − | − | − | − | + |
| D5 | + | +/− | − | − | − | − | + | + | + | − | − |
| E | − | − | + | − | − | + | − | + | + | − | − |
Positive and negative results obtained by PCR for ibeA (invasion of brain endothelium), iroN (catecholate siderophore receptor), sat (secreted autotransporter toxin), afa/draBC (Afa/Dr adhesins), afa operon FM955459, papG II (allele II of papG gene), papG III (allele III of papG gene), cnf1 (cytotoxic necrotizing factor type 1), hlyA (alpha-hemolysin), cdtB (cytolethal distending toxin) and neuC-K1 (K1 variant of group II capsule).
Most isolates of virotype A and B are sat-positive.
Isolates of virotype D3 carry genes sat and afa/draBC, or at least one of them. In addition, some afa/draBC strains are positive for afa operon FM955459.
Allele profile of the 23 ST131 E. coli isolates by the Pasteur Institute MLST scheme.
| PST |
|
|
|
|
|
|
|
| Serotype | Virotypes |
|
| 9 | 1 | 15 | 7 | 4 | 9 | 6 | 9 | O25b:H4 | A, B, C, D1, D2, D3 |
|
| 9 | 20 | 15 | 7 | 4 | 9 | 6 | 9 | O25b:H4 | D4, D5 |
|
| 9 | 20 | 15 | 7 | 4 | 9 | 6 | 129 | O25b:H4 | D4 |
|
| 9 | 234 | 15 | 7 | 4 | 9 | 6 | 9 | O25b:H4 | E |
|
| 9 | 134 | 74 | 134 | 4 | 72 | 1 | 9 | O16:H5 | C |
|
| 9 | 20 | 74 | 134 | 4 | 72 | 1 | 9 | O16:H5 | C |
|
| 9 | 134 | 74 | 134 | 4 | 162 | 1 | 9 | O16:H5 | C |
Virotypes in which the indicated PST was detected.
Figure 1Pulsed-field gel electrophoresis of XbaI-digested DNA from 23 ST131 E. coli isolates.
The dendrogram was obtained with the UPGMA algorithm based on the Dice similarity coefficient and applying 1% of tolerance in the band position. Isolate designation, O:H serotype, virotype, PST, virulence-gene score, final lethality (mice dead within 7 days/mice challenged), and fimH subtype are shown on the right.
Associations of molecular types, virulence-gene profiles and virulence patterns in the murine sepsis model of the 23 ST131 E. coli isolates studied.
| Isolate code | Serotype | Viro Type | PST | Lethality | Lethality | Final lethality | Final lethality+lesion | Complete virulence-gene profile | VG | ExPEC status |
| FV 9873 | O25b:H4 | A | 43 | 10 | 0 |
| 10 |
| 15 | Yes |
| FV 7563 | O25b:H4 | A | 43 | 10 | 0 |
| 10 |
| 15 | Yes |
| 35 BA | O25b:H4 | B | 43 | 2 | 5 |
| 10 |
| 16 | Yes |
| 25.27 | O25b:H4 | B | 43 | 10 | 0 |
| 10 |
| 15 | Yes |
| 20.22 | O25b:H4 | C | 43 | 10 | 0 |
| 10 |
| 14 | Yes |
| 45.09 | O25b:H4 | C | 43 | 4 | 4 |
| 10 |
| 14 | Yes |
| 28.65 | O25b:H4 | D1 | 43 | 2 | 8 |
| 10 |
| 13 | Yes |
| H1447 | O25b:H4 | D1 | 43 | 3 | 6 |
| 9 |
| 13 | Yes |
| FV 11171 | O25b:H4 | D2 | 43 | 0 | 0 |
| 9 |
| 19 | Yes |
| H2525 | O25b:H4 | D2 | 43 | 2 | 8 |
| 10 |
| 19 | Yes |
| H1659 | O25b:H4 | D3 | 43 | 0 | 3 |
| 7 |
| 15 | Yes |
| H2341 | O25b:H4 | D3 | 43 | 0 | 1 |
| 4 |
| 14 | Yes |
| FV 14025 | O25b:H4 | D4 | 9 | 3 | 7 |
| 10 |
| 15 | Yes |
| 83 BA | O25b:H4 | D4 | 9 | 0 | 0 |
| 8 |
| 12 | No |
| FV 17616 | O25b:H4 | D4 | 527 | 5 | 4 |
| 9 |
| 14 | Yes |
| 61 BA | O25b:H4 | D5 | 9 | 4 | 1 |
| 5 |
| 20 | Yes |
| 50 BA | O25b:H4 | D5 | 9 | 0 | 0 |
| 5 |
| 20 | Yes |
| FV17578 | O25b:H4 | E | 621 | 0 | 1 |
| 10 |
| 18 | Yes |
| FV 17543 | O25b:H4 | E | 621 | 0 | 1 |
| 10 |
| 18 | Yes |
| FV 17539 | O16:H5 | C | 625 | 0 | 5 |
| 10 |
| 11 | No |
| FV 17598 | O16:H5 | C | 506 | 0 | 5 |
| 10 |
| 11 | No |
| H2623 | O16:H5 | C | 567 | 0 | 8 |
| 10 |
| 11 | No |
| FV 13998 | O16:H5 | C | 506 | 3 | 7 |
| 10 |
| 12 | Yes |
Virotypes (including new assigned E) and subtypes of virotype D.
Number of mice dead within 24 h postinjection. Isolates were classified as rapidly lethal if ≥80% of mice challenged with them died within 24 h postinjection.
Number of mice dead within 25–48 h postinjection.
Total number of mice dead within 7 days of experiment.
Total number of mice dead within 7 days of experiment (final lethality) plus number of mice with local presence of lesion (acute inflammation in the region of bacterial inoculation) when euthanatized.
Virulence-gene profile obtained by PCR for detection of 40 ExPEC-associated virulence genes.
Virulence-gene (VG) score calculated as the sum of all virulence genes detected in an isolate.
ExPEC status defined as presence ≥2 of papEF, sfa/focDE, afa/draBC, iutA and kpsM II.
Isolates FV 9873, FV 7563 and H1659 exhibited afa operon FM955459.
Figure 2Projections of the serotypes (O25:H4 and O16:H5), the 7 PSTs (PST9, PST43, PST506, PST525, PST567, PST621 and PST625), the 9 virotypes (VA, VB, VC, VD1, VD2, VD3, VD4, VD5 and VE), the mouse lethality occurring in less than 24 hours (Let ≤24 h), the lethality in the mouse model as killer (K), intermediate killer (IK) and non-killer (NK), the local presence of acute inflammation (lesion), the high (VSH) or low (VSL) virulence score and 25 virulence genes (listed as in Table 4) characterising the 23 E. coli strains on the plane F1/F3 computed from the factorial analysis of correspondence.
Only one square is indicated when several variables are projected at the same position.